levomilnacipran 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4864 96847-54-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • levomilnacipran
  • levomilnacipran hydrochloride
  • fetzima
  • levomilnacipran HCl
a selective serotonin and norepinephrine reuptake inhibitor (SNRI), mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system
  • Molecular weight: 246.35
  • Formula: C15H22N2O
  • CLOGP: 1.91
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.33
  • ALOGS: -2.30
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 mg O

ADMET properties:

PropertyValueReference
fu (Fraction unbound in plasma) 0.68 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability) 0.88 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
July 25, 2013 FDA FOREST LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blepharospasm 333.13 36.97 68 1946 5928 63481080
Taste disorder 277.36 36.97 68 1946 13594 63473414
Epilepsy 235.70 36.97 69 1945 26996 63460012
Memory impairment 173.24 36.97 78 1936 104180 63382828
Migraine 154.90 36.97 72 1942 103274 63383734
Gastrooesophageal reflux disease 153.87 36.97 70 1944 95569 63391439
Paraesthesia 131.89 36.97 74 1940 156892 63330116
Hypoaesthesia 124.38 36.97 73 1941 168320 63318688
Abdominal pain upper 113.13 36.97 74 1940 206370 63280638
Persistent genital arousal disorder 96.22 36.97 15 1999 271 63486737
Drug intolerance 74.43 36.97 68 1946 308593 63178415
Vomiting 62.28 36.97 82 1932 559535 62927473
Suicidal ideation 59.25 36.97 32 1982 62389 63424619
Pain 42.33 36.97 80 1934 740548 62746460
Off label use 39.92 36.97 74 1940 674388 62812620
Serotonin syndrome 39.73 36.97 19 1995 28663 63458345

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blepharospasm 243.66 40.01 48 1482 5803 79737055
Taste disorder 196.09 40.01 48 1482 15775 79727083
Epilepsy 151.02 40.01 48 1482 40812 79702046
Memory impairment 133.13 40.01 57 1473 111677 79631181
Migraine 122.15 40.01 50 1480 87443 79655415
Gastrooesophageal reflux disease 113.70 40.01 50 1480 104196 79638662
Paraesthesia 99.82 40.01 54 1476 176269 79566589
Hypoaesthesia 98.96 40.01 54 1476 179298 79563560
Persistent genital arousal disorder 96.14 40.01 14 1516 267 79742591
Abdominal pain upper 85.27 40.01 53 1477 223766 79519092
Drug intolerance 63.33 40.01 47 1483 264072 79478786
Vomiting 41.67 40.01 57 1473 665771 79077087

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX28 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
FDA MoA N0000000102 Norepinephrine Uptake Inhibitors
FDA MoA N0000000109 Serotonin Uptake Inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D000068760 Serotonin and Noradrenaline Reuptake Inhibitors
FDA EPC N0000175749 Serotonin and Norepinephrine Reuptake Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000
Angle-closure glaucoma contraindication 392291006 DOID:13550




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.64 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 120MG BASE FETZIMA ABBVIE N204168 July 25, 2013 RX CAPSULE, EXTENDED RELEASE ORAL RE43879 Jan. 11, 2026 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 20MG BASE FETZIMA ABBVIE N204168 July 25, 2013 RX CAPSULE, EXTENDED RELEASE ORAL RE43879 Jan. 11, 2026 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 40MG BASE FETZIMA ABBVIE N204168 July 25, 2013 RX CAPSULE, EXTENDED RELEASE ORAL RE43879 Jan. 11, 2026 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 80MG BASE FETZIMA ABBVIE N204168 July 25, 2013 RX CAPSULE, EXTENDED RELEASE ORAL RE43879 Jan. 11, 2026 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 120MG BASE FETZIMA ABBVIE N204168 July 25, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8481598 March 2, 2031 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 20MG BASE FETZIMA ABBVIE N204168 July 25, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8481598 March 2, 2031 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 40MG BASE FETZIMA ABBVIE N204168 July 25, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8481598 March 2, 2031 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 80MG BASE FETZIMA ABBVIE N204168 July 25, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8481598 March 2, 2031 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 7.95 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 7.04 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Sodium-dependent dopamine transporter Transporter IC50 5.49 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 8.07 CHEMBL
Glutamate NMDA receptor Ion channel IC50 5.20 CHEMBL

External reference:

IDSource
D10072 KEGG_DRUG
4032886 VUID
N0000189503 NUI
4032886 VANDF
CHEBI:136040 CHEBI
CHEMBL99946 ChEMBL_ID
7435 IUPHAR_LIGAND_ID
175131-60-9 SECONDARY_CAS_RN
DB08918 DRUGBANK_ID
1433211 RXNORM
204684 MMSL
29577 MMSL
31358 MMSL
d08114 MMSL
015223 NDDF
015224 NDDF
C3541367 UMLSCUI
D000078862 MESH_DESCRIPTOR_UI
CHEMBL2105732 ChEMBL_ID
8740 INN_ID
6917779 PUBCHEM_CID
UGM0326TXX UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2212 CAPSULE, EXTENDED RELEASE 120 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2212 CAPSULE, EXTENDED RELEASE 120 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2212 CAPSULE, EXTENDED RELEASE 120 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2220 CAPSULE, EXTENDED RELEASE 20 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2220 CAPSULE, EXTENDED RELEASE 20 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2220 CAPSULE, EXTENDED RELEASE 20 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2240 CAPSULE, EXTENDED RELEASE 40 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2240 CAPSULE, EXTENDED RELEASE 40 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2240 CAPSULE, EXTENDED RELEASE 40 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2280 CAPSULE, EXTENDED RELEASE 80 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2280 CAPSULE, EXTENDED RELEASE 80 mg ORAL NDA 35 sections
Fetzima HUMAN PRESCRIPTION DRUG LABEL 1 0456-2280 CAPSULE, EXTENDED RELEASE 80 mg ORAL NDA 35 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-411 CAPSULE, EXTENDED RELEASE 20 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-411 CAPSULE, EXTENDED RELEASE 20 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-411 CAPSULE, EXTENDED RELEASE 20 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-437 CAPSULE, EXTENDED RELEASE 80 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-437 CAPSULE, EXTENDED RELEASE 80 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-437 CAPSULE, EXTENDED RELEASE 80 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-455 CAPSULE, EXTENDED RELEASE 120 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-455 CAPSULE, EXTENDED RELEASE 120 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-455 CAPSULE, EXTENDED RELEASE 120 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-960 CAPSULE, EXTENDED RELEASE 40 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-960 CAPSULE, EXTENDED RELEASE 40 mg ORAL ANDA 29 sections
Levomilnacipran HUMAN PRESCRIPTION DRUG LABEL 1 65162-960 CAPSULE, EXTENDED RELEASE 40 mg ORAL ANDA 29 sections